Donepezil Tied to Risk for Overactive Bladder
Risk for overactive bladder varies across individual cholinesterase inhibitor drugs
Risk for overactive bladder varies across individual cholinesterase inhibitor drugs
Outcomes even worse for hospitalized patients with incontinence who require treatment of incontinence-associated dermatitis
This slideshow show drug information for Gemtesa. Click here for the complete Gemtesa monograph.
Gemtesa is an oral, once-daily, small molecule beta-3 adrenergic agonist.
Both formulations are indicated for patients aged 3 years and older; however, the tablet formulation is specifically approved for patients weighing 35kg or more.
Prevalence of nocturia reduced among postmenopausal women who selected systemic hormone therapy compared with no treatment
In a small study, add-on vibegron appeared well-tolerated and clinically effective among men with persistent OAB.
The approval is supported by data from a phase 3 study that assessed the efficacy and safety of Botox in patients aged 5 to 17 years with urinary incontinence due to NDO and using clean intermittent catheterization.
Researchers conducted meta-analyses to investigate the real rates of persistence and adherence to overactive bladder drug therapies and moderating factors.
The submissions are supported by data from a phase 3 study that evaluated mirabegron in 91 patients aged 3 to 17 years with NDO on clean intermittent catheterization.